OptiNose, Inc. (OPTN): Price and Financial Metrics


OptiNose, Inc. (OPTN): $2.95

0.20 (+7.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

OPTN POWR Grades


  • Growth is the dimension where OPTN ranks best; there it ranks ahead of 80.19% of US stocks.
  • OPTN's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • OPTN ranks lowest in Momentum; there it ranks in the 9th percentile.

OPTN Stock Summary

  • OptiNose Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 3.32% of US listed stocks.
  • OPTN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 0.71% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for OPTN comes in at -37.16% -- higher than that of just 7.85% of stocks in our set.
  • Stocks that are quantitatively similar to OPTN, based on their financial statements, market capitalization, and price volatility, are NLOK, SIEN, CSII, ESTA, and ATRI.
  • OPTN's SEC filings can be seen here. And to visit OptiNose Inc's official web site, go to www.optinose.com.

OPTN Valuation Summary

  • In comparison to the median Healthcare stock, OPTN's price/sales ratio is 77.97% lower, now standing at 2.5.
  • Over the past 47 months, OPTN's price/earnings ratio has gone down 72.4.
  • Over the past 47 months, OPTN's price/sales ratio has gone down 11.7.

Below are key valuation metrics over time for OPTN.

Stock Date P/S P/B P/E EV/EBIT
OPTN 2021-08-31 2.5 -4.2 -1.6 -2.3
OPTN 2021-08-30 2.5 -4.3 -1.7 -2.4
OPTN 2021-08-27 2.5 -4.2 -1.6 -2.3
OPTN 2021-08-26 2.5 -4.1 -1.6 -2.3
OPTN 2021-08-25 2.4 -4.0 -1.6 -2.3
OPTN 2021-08-24 2.4 -4.0 -1.6 -2.3

OPTN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OPTN has a Quality Grade of C, ranking ahead of 33.52% of graded US stocks.
  • OPTN's asset turnover comes in at 0.372 -- ranking 127th of 677 Pharmaceutical Products stocks.
  • ALT, CLVS, and FOLD are the stocks whose asset turnover ratios are most correlated with OPTN.

The table below shows OPTN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.372 0.861 -0.687
2021-03-31 0.317 0.854 -0.758
2020-12-31 0.282 0.847 -0.844
2020-09-30 0.258 0.832 -0.995
2020-06-30 0.251 0.840 -1.196
2020-03-31 0.225 0.841 -1.335

OPTN Price Target

For more insight on analysts targets of OPTN, see our OPTN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.00 Average Broker Recommendation 1.4 (Strong Buy)

OPTN Stock Price Chart Interactive Chart >

Price chart for OPTN

OPTN Price/Volume Stats

Current price $2.95 52-week high $5.11
Prev. close $2.75 52-week low $2.32
Day low $2.74 Volume 220,751
Day high $3.04 Avg. volume 382,329
50-day MA $2.75 Dividend yield N/A
200-day MA $3.49 Market Cap 157.26M

OptiNose, Inc. (OPTN) Company Bio


OptiNose, Inc. focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. The company was founded in 2010 and is based in Yardley, Pennsylvania.


OPTN Latest News Stream


Event/Time News Detail
Loading, please wait...

OPTN Latest Social Stream


Loading social stream, please wait...

View Full OPTN Social Stream

Latest OPTN News From Around the Web

Below are the latest news stories about OptiNose Inc that investors may wish to consider to help them evaluate OPTN as an investment opportunity.

Optinose to Present at the Cantor Virtual Global Healthcare Conference

YARDLEY, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 8:40 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of

Yahoo | September 22, 2021

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

YARDLEY, Pa., Aug. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose , Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 60,000 shares of its common stock to seven new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Intrado Digital Media | August 25, 2021

Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights

Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020

Intrado Digital Media | August 11, 2021

OptiNose (OPTN) Reports Q2 Loss, Tops Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -2.33% and 5.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 11, 2021

Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights

Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020 Second quarter 2021 XHANCE prescriptions increased 33% from second quarter 2020 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 202

Yahoo | August 11, 2021

Read More 'OPTN' Stories Here

OPTN Price Returns

1-mo 4.98%
3-mo -9.79%
6-mo -16.43%
1-year -23.97%
3-year -78.64%
5-year N/A
YTD -28.74%
2020 -55.10%
2019 48.71%
2018 -67.20%
2017 N/A
2016 N/A

Continue Researching OPTN

Here are a few links from around the web to help you further your research on OptiNose Inc's stock as an investment opportunity:

OptiNose Inc (OPTN) Stock Price | Nasdaq
OptiNose Inc (OPTN) Stock Quote, History and News - Yahoo Finance
OptiNose Inc (OPTN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 3.5963 seconds.